Header Logo

Connection

ERIC JONASCH to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications ERIC JONASCH has written about Antineoplastic Agents.
ERIC JONASCH
Connection Strength
2.511
Antineoplastic Agents
  1. Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 05; 27(5):802-805.
    View in: PubMed
    Score: 0.159
  2. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018 06 01; 36(16):1588-1593.
    View in: PubMed
    Score: 0.129
  3. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017 04 01; 28(4):804-808.
    View in: PubMed
    Score: 0.120
  4. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.119
  5. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.107
  6. Kidney cancer: current and novel treatment options. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):679-81.
    View in: PubMed
    Score: 0.105
  7. The impact of FGFR1 and FRS2a expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer. 2015 Apr 18; 15:304.
    View in: PubMed
    Score: 0.105
  8. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin. 2014 Nov; 30(11):2343-53.
    View in: PubMed
    Score: 0.100
  9. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Curr Med Res Opin. 2014 Oct; 30(10):2041-50.
    View in: PubMed
    Score: 0.100
  10. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 Mar; 191(3):611-8.
    View in: PubMed
    Score: 0.094
  11. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
    View in: PubMed
    Score: 0.086
  12. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec; 22(12):2661-2666.
    View in: PubMed
    Score: 0.083
  13. Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol. 2011 Nov; 7(11):1247-53.
    View in: PubMed
    Score: 0.083
  14. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther. 2011 Jun; 11(6):913-20.
    View in: PubMed
    Score: 0.080
  15. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther. 2010 Dec; 10(12):1883-9.
    View in: PubMed
    Score: 0.078
  16. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010 Jun; 5(2):113-8.
    View in: PubMed
    Score: 0.075
  17. Prognostic and predictive factors in the targeted therapy era: filling in the blanks. Curr Oncol Rep. 2010 May; 12(3):143-5.
    View in: PubMed
    Score: 0.074
  18. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7.
    View in: PubMed
    Score: 0.066
  19. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046.
    View in: PubMed
    Score: 0.041
  20. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev. 2020 Sep; 89:102062.
    View in: PubMed
    Score: 0.038
  21. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45.
    View in: PubMed
    Score: 0.037
  22. Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nat Metab. 2019 04; 1(4):431-444.
    View in: PubMed
    Score: 0.034
  23. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018 11; 104:188-194.
    View in: PubMed
    Score: 0.034
  24. Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. Pract Radiat Oncol. 2018 Sep - Oct; 8(5):e262-e265.
    View in: PubMed
    Score: 0.032
  25. Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Target Oncol. 2017 06; 12(3):333-340.
    View in: PubMed
    Score: 0.030
  26. Incorporating New Systemic Therapies in Kidney Cancer Treatment. J Natl Compr Canc Netw. 2017 05; 15(5S):703-705.
    View in: PubMed
    Score: 0.030
  27. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.030
  28. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer. 2017 04; 15(2):e205-e208.
    View in: PubMed
    Score: 0.029
  29. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Curr Med Res Opin. 2016; 32(4):741-7.
    View in: PubMed
    Score: 0.028
  30. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. J Med Econ. 2016; 19(5):462-8.
    View in: PubMed
    Score: 0.028
  31. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.027
  32. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.026
  33. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother. 2015 Apr; 16(6):805-19.
    View in: PubMed
    Score: 0.026
  34. Renal cell carcinoma. BMJ. 2014 Nov 10; 349:g4797.
    View in: PubMed
    Score: 0.025
  35. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):175-82.
    View in: PubMed
    Score: 0.024
  36. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82.
    View in: PubMed
    Score: 0.024
  37. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013 Nov; 14(12):1233-42.
    View in: PubMed
    Score: 0.024
  38. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol. 2011 Aug; 6(3):189-98.
    View in: PubMed
    Score: 0.020
  39. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol. 2011 Aug; 6(3):144-50.
    View in: PubMed
    Score: 0.020
  40. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
    View in: PubMed
    Score: 0.019
  41. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.019
  42. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5.
    View in: PubMed
    Score: 0.019
  43. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 2008 Sep-Oct; 14(5):315-9.
    View in: PubMed
    Score: 0.017
  44. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8.
    View in: PubMed
    Score: 0.016
  45. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer. 2000 Jul 15; 89(2):356-62.
    View in: PubMed
    Score: 0.009
  46. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget. 2017 Jun 27; 8(26):42149-42158.
    View in: PubMed
    Score: 0.008
  47. The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics. 2015 Jul 20; 42(7):343-53.
    View in: PubMed
    Score: 0.007
  48. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer. 2014 Oct; 12(5):348-53.
    View in: PubMed
    Score: 0.006
  49. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. 2011 Nov 01; 117(21):4958-65.
    View in: PubMed
    Score: 0.005
  50. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012 Jan; 23(1):46-52.
    View in: PubMed
    Score: 0.005
  51. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053.
    View in: PubMed
    Score: 0.005
  52. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.